Clinical Trials Browser

Phase 1 × INDUSTRY × Disease Progression × Clear all

Colonic Neoplasms, Glioblastoma, Lung Neoplasms, Neoplasms, Pancreatic Neoplasms, Disease Progression

NCT05153330 2025-07-03

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Disease Progression, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02766699 2025-06-03

CerebralEDV

Phase 1 Completed

9 enrolled

CNS

Brain Neoplasms, Glioblastoma, Neoplasms, Neoplasms by Site, Recurrence, Disease Progression

NCT02189343 2019-11-21

Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Phase 1 Completed

16 enrolled

Plasma cell

Disease, Multiple Myeloma, Recurrence, Disease Progression

NCT02586987 2019-11-18

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

Phase 1 Completed

58 enrolled

BreastDermatologicGastrointestinalThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Lung Neoplasms, Melanoma, Colorectal Neoplasms, Disease Progression

NCT01692262 2014-06-19

PYRUS

Phase 1 Completed

59 enrolled

Genitourinary

Prostatic Neoplasms, Disease Progression

Clinical Trials

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL

CerebralEDV

Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

PYRUS